Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2024 · 10-Q
Revenue$1.54M$1.54M−73.5% vs Q1 2023 Net Income-$4.67M-$4.67MN/M vs Q1 2023 EPS Diluted-$4.17-$4.17N/M vs Q1 2023 Gross Profit$163,615−90.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$1,307,925N/M Free Cash Flowderived-$1,307,925N/M Margins · derivedGross margin10.6%−19.6 pt vs Q1 2023
Operating margin-211.0%−151.6 pt vs Q1 2023
Net margin-303.2%−239.1 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end